Stem cells injected into eye aim to halt blindness
NCT ID NCT02286089
First seen Nov 05, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This study tests a stem cell therapy called OpRegen for people with advanced dry age-related macular degeneration (geographic atrophy). Researchers inject retinal pigment epithelium cells derived from human embryonic stem cells into the eye to see if they can safely replace damaged cells and slow vision loss. The trial involves 24 participants aged 50 and older with poor central vision.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Eye Institute
Cincinnati, Ohio, 45242, United States
-
Hadassah Medical Center
Jerusalem, 9112001, Israel
-
Kaplan Medical Center
Rehovot, 76100, Israel
-
Mid Atlantic Retina
Philadelphia, Pennsylvania, 19107, United States
-
Rabin Medical Center
Petah Tikva, 4941492, Israel
-
Tel Aviv Sourasky Medical Center
Tel Aviv, 6423906, Israel
-
West Coast Retina Medical Group
San Francisco, California, 94109, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OpRegen (human embryonic stem cell-derived retinal pigment epithelium cells)
What this could lead to
If successful, this could slow or stop vision loss from dry age-related macular degeneration, offering a new treatment option for a currently untreatable condition.
What could go wrong
This is an early-phase trial with only 24 participants, so results may not apply to everyone. Risks include inflammation, retinal detachment, or the cells not surviving long-term.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.